Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACB2003 4

Next Previous
X
Search
Drug Profile

ACB2003 4

Alternative Names: ACB2003-4; ACB2003.4; LX 2931; LX-3305

Latest Information Update: 03 Jan 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer AC Bioscience; Dermecular Therapeutics; Lexicon Pharmaceuticals
  • Class Alcohols; Antineoplastics; Antirheumatics; Imidazoles; Oximes; Skin disorder therapies; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate lyase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pancreatic cancer
  • Discontinued Duchenne muscular dystrophy; Rheumatoid arthritis; Skin disorders

Most Recent Events

  • 03 Jan 2024 AC Bioscience plans a phase IIa trial in Pancreatic cancer in France in early 2024 (AC Bioscience pipeline, January 2024)
  • 25 Nov 2022 Preclinical trials in Pancreatic cancer in Switzerland (PO) (AC BioScience pipeline, October 2022)
  • 11 Mar 2021 Chemical structure information added

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top